OptiSeq™ Pan-Cancer Panel Service (65-Gene)
Sample to report within 10 business days
DiaDiaCarta offers a sample-to-report OptiSeq™ Targeted Sequencing cancer service at its state-of-the-art facility. The liquid biopsy/FFPE sample prep workflow provides clients with fast turnaround time and accurate VAF detection process. Variants are classified based on guidelines with a focus on actionable content from drug labels and clinical trials. Information is presented in a final report. The whole process from samples (blood/FFPE) to report is completed within 10 business days in our laboratory.
OptiSeq™ Pan-Cancer Panel is designed to target 2,900 commonly observed mutational positions (hotspots) from 65 oncogenes and tumor suppressor genes. This panel contains a single pool of 601 primer pairs and the average amplicon length is 145 bp – perfectly suitable for ctDNA and FFDNA sequencing.
OptiSeq™ Pan-Cancer Gene Panel (65 Genes)
| ABL1 | AKT1 | ALK | APC | ATM | BRAF | BRCA1 |
|---|---|---|---|---|---|---|
| BRCA2 | CDH1 | CDKN2A | CSF1R | CTNNB1 | DDR2 | DNMT3A |
| EGFR | ERBB2 | ERBB3 | ERBB4 | EZH2 | FBXW7 | FGFR1 |
| FGFR2 | FGFR3 | FLT3 | FOXL2 | GNA11 | GNAQ | GNAS |
| HNF1A | HRAS | IDH1 | IDH2 | JAK2 | JAK3 | KDR |
| KIT | KRAS | MAP2K1 | MET | MLH1 | MPL | MSH6 |
| MTOR | NF1 | NF2 | NOTCH1 | NPM1 | NRAS | PDGFRA |
| PIK3CA | PIK3R1 | PTCH1 | PTEN | PTPN11 | RB1 | RET |
| SMAD4 | SMARCB1 | SMO | SRC | STK11 | TERT | TP53 |
| TSC1 | VHL |
Advantages of OptiSeq™ Pan-Cancer Panel
samples tested
Liquid biopsy (blood/ccfDNA) and FFPE samples (tissue/DNA)
highly sensitive
Highly sensitive NGS test allows as low as 1% variant allele frequency (VAF) detection
Fast turnaround time
Sample receipt to clinical report within 10 days. No deep sequencing
Extremely uniform
100% observed uniformity at ≥ 0.2X mean depth and 97% observed uniformity at ≥ 0.5X
Low dna input needed
10ng for detection of somatic mutations (SNP); 100pg for germline mutations
Report to Clinicians
Comprehensive clinically significant variants, FDA-approved therapies and clinical trials
OptiSeq™ Pan-Cancer Panel Service Sample Report
The research NGS report also includes information regarding variant details, FDA-approved therapies for this indication, therapies associated with resistance, clinical trials, genes tested, methods and limitations, and selected citations.
Streamlined Workflow for OptiSeq™ Pan-Cancer Panel
Step 1: Sample prep & QC
Step 2: Target enrichment
Step 3: Library Preparation & QC & Template
Step 4: Sequencing Run
Step 5: Data Analysis
Step 6: Reporting
OptiSeq™ Pan-Cancer Panel Specifications
Sample Type
Liquid biopsy (blood/cfDNA) and FFPE samples (tissue/DNA)
Species
Human
Recommended DNA Input (Amount)
10ng for detection of somatic mutations (SNP); 100pg for germline mutations
Sequencing Platform
Illumina Sequencers (MiniSeq, MiSeq, NextSeq, HiSeq)
Enrichment Method
Multiplex PCR
Number of Primer Pairs
601
Number of Primer Pools
1
Number of Target Genes
65
Target Region Size (bp)
55199
Amplicon Size
Average 146bp (from 125-175bp)
Sample Multiplexing (at ~2000x mean coverage)
Miseq 2×150 Read Length: ~25 samples
NextSeq Series Mid Output 2×150 Read Length: ~200
NextSeq Series High Output @ 2×150 Read Length: ~600
Coverage Uniformity (at ~ ≥ 0.2x Mean Coverage)
> 95%
On-target Reads % (% reads aligned to target regions out of total aligned reads)
> 95%
Turnaround Time
Sample receipt to report within 10 days